Comparison of tumor responses by modified WHO and new RECIST criteria from a phase II study of first-line brivanib in hepatocellular carcinoma (HCC) - Lencioni, R; Raoul, J-L; Park, J W; Baudelet, C; Walters, I
. Accessed May 3, 2017